Flecainide is a strong medicine used to treat irregular heartbeats. It helps control fast or slow heart rhythms. It's a powerful drug, so it needs careful monitoring by a doctor.
Every report comes from a Lived member, sent anonymously.
Have you tried Flecainide for AFib (Atrial Fibrillation)?
Flecainide is a prescription heart rhythm medicine (an antiarrhythmic) taken as a tablet. It is mainly used to prevent recurring episodes of two kinds of fast, irregular rhythm that start in the upper part of the heart: paroxysmal atrial fibrillation or atrial flutter, where "paroxysmal" means the episodes come and go, and supraventricular tachycardia (SVT), sudden bursts of a very fast but regular heartbeat. For these uses it is approved for people whose hearts are otherwise structurally healthy and whose symptoms are disruptive. It was once sold under the brand name Tambocor, which has been discontinued in the US; it is now available as generic flecainide. Flecainide is also approved for certain life-threatening ventricular arrhythmias (dangerous rhythms starting in the heart's lower chambers), and in that setting it is started in the hospital. Specialists sometimes use it for catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited rhythm disorder triggered by exercise or stress, usually alongside a beta-blocker. Flecainide treats symptoms rather than extending life: it has not been shown to help people live longer or to prevent sudden death. For atrial fibrillation, it does not replace a blood thinner when one is needed to prevent stroke. Other options include different rhythm medicines and catheter ablation, a procedure that targets the tissue causing the abnormal rhythm.
The heartbeat depends on electrical signals spreading in an orderly way through the heart muscle. Those signals travel as sodium moves into heart cells through tiny channels. Flecainide partly blocks these sodium channels, which slows how fast signals spread. That makes it harder for the stray, self-sustaining electrical loops behind many rhythm problems to start or keep going. The same slowing has a side effect worth understanding. In atrial flutter, flecainide can slow the upper chambers' racing rhythm just enough that every beat passes to the lower chambers, which can suddenly make the pulse faster rather than slower. For that reason, people taking flecainide for atrial fibrillation or flutter usually also take a beta-blocker or the calcium channel blocker diltiazem, medicines that limit how many signals reach the lower chambers. Flecainide also slightly weakens the heart's pumping force, which is one reason it is reserved for hearts that are otherwise healthy.
Flecainide comes as tablets, usually taken every 12 hours at about the same times each day, with or without food. The prescriber starts with a low dose and raises it gradually, no more often than every four days. Flecainide stays in the body a long time, so each new dose takes three to five days to reach a steady level, and faster increases raise the risk of rhythm problems. Once the rhythm is controlled, some people can step down to a lower dose. People with significant kidney or liver disease, or who also take amiodarone, start lower and may have blood levels of flecainide checked. Some people with occasional atrial fibrillation episodes use a "pill-in-the-pocket" approach instead of daily tablets: a single larger dose taken when an episode starts, usually with a rate-slowing medicine taken beforehand. This is arranged only for people without structural heart disease, and the first dose is normally tested in a setting where the heart rhythm can be monitored. It should not be tried on one's own. If a daily dose is missed, take it when remembered unless the next dose is close; do not double up. Do not stop flecainide suddenly without a plan from the prescriber, since the original rhythm problem can return.
Dizziness or lightheadedness and changes in vision, such as blurring or trouble focusing, are the most common side effects, and they become more likely at higher doses. Headache, nausea, tiredness, shortness of breath, tremor and constipation also occur. These are worth reporting, because a dose adjustment often helps. The most important risk is that flecainide, like other rhythm medicines, can itself cause new or worse abnormal rhythms, most often in the first weeks or after a dose increase. It can also bring on or worsen heart failure and, less often, slow the heartbeat too much. Call the prescriber right away for a fast, pounding or irregular heartbeat, chest pain, new or worsening shortness of breath, or swelling of the feet, ankles or legs. Fainting, or a racing heartbeat with chest pain, severe breathlessness or a feeling of being about to pass out, needs emergency care: call 911. Rarely, flecainide has been linked to liver problems or blood disorders. Yellowing of the skin or eyes, or unusual bleeding or bruising, should be reported promptly.
Flecainide should not be used by people who have had a heart attack or who have significant structural heart disease, such as scarring of the heart muscle or heart failure with reduced pumping strength. In a large trial of people who had recently had a heart attack, those given flecainide had more deaths and cardiac arrests than those given a placebo. This finding is the basis of the medicine's boxed warning, and it is why it is generally reserved for people whose rhythm problem is disabling and whose heart is otherwise healthy. It is also not recommended for permanent (long-standing) atrial fibrillation. It is not used in people with certain kinds of heart block, a problem with signals passing between the upper and lower chambers, unless they have a pacemaker. People who have a pacemaker or defibrillator should tell the device team before starting, as flecainide can raise the energy the device needs to pace the heart, so its settings may need checking. Several medicines change flecainide's effects. Amiodarone, another rhythm medicine, can double flecainide levels, so the dose is usually halved and monitored. Verapamil (a calcium channel blocker used for blood pressure and heart rate) and disopyramide (an older rhythm medicine) are generally avoided in combination because they also weaken the heart's pumping. Quinidine, another older rhythm medicine, and the heartburn medicine cimetidine can raise flecainide levels, and flecainide slightly raises levels of digoxin, a heart medicine used to slow the heart rate in atrial fibrillation or support pumping in heart failure. Low or high potassium makes rhythm problems more likely, so it is corrected before treatment. A strictly vegetarian diet can slow how quickly the body clears flecainide. Tell the prescriber about all medicines and supplements, and about pregnancy, plans for it or breastfeeding; flecainide is sometimes used in pregnancy when the benefit outweighs the risk.
Starting flecainide usually involves an electrocardiogram (ECG), a tracing of the heart's electrical activity, before treatment and again after it begins or the dose changes, to check that the signal-slowing effect is within a safe range. Many people start as outpatients; those with life-threatening ventricular rhythms start in the hospital. Because levels settle over several days, the full effect of a dose is judged after about a week, not after the first tablet. For atrial fibrillation, the realistic goal is fewer and shorter episodes rather than none; in early trials, most people still had some episodes, but they came much less often. Results are often stronger for SVT. If flecainide does not control symptoms well or causes troublesome side effects, a different rhythm medicine or catheter ablation may be discussed. Treatment typically continues as long as it is helping, with periodic ECG tracings and checkups. Any new diagnosis of heart disease, such as a heart attack or reduced pumping function, changes whether flecainide is still safe, so it is worth reviewing the medicine whenever heart health changes.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Flecainide, what you've noticed, or ask the community a question.